A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
for
Relapsed or Refractory Multiple Myeloma
Location: Houston TX, Duarte CA
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07681596
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
for
Healthy Participants
Location: Glendale CA
Sponsor: AstraZeneca
Sex: All
Age: 18 - 55
Code: NCT06951880
Phase 1, Recruiting
Active & Responsive
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
for
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA),
Location: Toronto, Hamilton, Cleveland OH
Sponsor: AstraZeneca
Sex: All
Age: 6+
Code: NCT07444567
Phase 3, Recruiting
Active & Responsive
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
for
Type 2 Diabetes Mellitus
Location: Toronto, Ocoee FL, Vancouver
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07664553
Phase 3, Recruiting
Active & Responsive
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
for
High-risk Muscle Invasive Urothelial Carcinoma
Location: Hamilton, Barrie
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07720284
Phase 3, Recruiting
Active & Responsive
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
for
Stomatitis
Location: Wynnewood PA, East Syracuse NY, Fairfax VA, Wilson NC,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07357597
Phase 4, Recruiting
Active & Responsive
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, New York NY, Montreal, Winston-Salem NC,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT07391657
Phase 3, Recruiting
Active & Responsive
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
for
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy),
Location: Stony Brook NY, New York NY, Montreal, Baltimore MD,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06535607
Phase 2, Recruiting
Active & Responsive
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
for
Healthy Participants, Obesity
Location: Brooklyn MD, Glendale CA
Sponsor: AstraZeneca
Sex: All
Age: 18 - 65
Code: NCT07511205
Phase 1, Recruiting
Active & Responsive
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
for
Obesity or Overweight, Weight-Related Comorbidity,
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.
for
Hypercholesterolaemia
Location: Sherbrooke, Millville NJ, Stouffville,
Sponsor: AstraZeneca
Sex: All
Age: 18 - 70+
Code: NCT07619131
Phase 3, Recruiting
Active & Responsive
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
for
Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV,
Location: Halifax, Montreal, Toronto, Calgary
Sponsor: AstraZeneca
Sex: All
Age: 18
Code: NCT07509151
Phase 3, Recruiting
Active & Responsive
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
for
Metastatic Castration-resistant Prostate Cancer
Location: New York NY, Montreal, Myrtle Beach SC, Miami FL,
Sponsor: AstraZeneca
Sex: Male
Age: 18+
Code: NCT07611110
Phase 3, Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
for
HER2-positive Gastric Cancer,
Location: Chicoutimi, New York NY, Albany NY, Summit NJ, Montreal,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06764875
Phase 3, Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure